Compare PHR & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHR | LXRX |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.2M | 660.9M |
| IPO Year | 2019 | 2000 |
| Metric | PHR | LXRX |
|---|---|---|
| Price | $8.37 | $1.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 2 |
| Target Price | ★ $22.47 | $4.15 |
| AVG Volume (30 Days) | 2.5M | ★ 2.6M |
| Earning Date | 03-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.92 | 77.78 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $480,591,000.00 | $49,803,000.00 |
| Revenue This Year | $16.10 | N/A |
| Revenue Next Year | $8.95 | N/A |
| P/E Ratio | $209.25 | ★ N/A |
| Revenue Growth | 14.48 | ★ 60.24 |
| 52 Week Low | $7.77 | $0.36 |
| 52 Week High | $32.76 | $1.83 |
| Indicator | PHR | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.73 | 50.40 |
| Support Level | N/A | $1.47 |
| Resistance Level | $12.68 | $1.65 |
| Average True Range (ATR) | 0.61 | 0.11 |
| MACD | -0.27 | -0.02 |
| Stochastic Oscillator | 13.09 | 35.71 |
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.